Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

EVI1 drives leukemogenesis through aberrant activation of ERG

ABSTRACT: EVI1 drives leukemogenesis through aberrant activation of ERG

PROVIDER: PRJNA800809 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17771500.fastq.gz	Fastqsanger.gz
	SRR17771501.fastq.gz	Fastqsanger.gz
	SRR17771502.fastq.gz	Fastqsanger.gz
	SRR17771503.fastq.gz	Fastqsanger.gz
	SRR17771504.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 40

Similar Datasets

EVI1 drives leukemogenesis through aberrant activation of ERG

Project description:Chromosomal rearrangements involving EVI1 (MECOM) define a subtype of acute myeloid leukemia (AML) that is associated with a two-year survival rate of <10%. Gene regulatory functions of EVI1 are largely elusive and no targeted therapeutics exist. We developed experimentally tractable murine and human leukemia models that recapitulate phenotypic and transcriptional features of EVI1-rearranged AML and enable large-scale loss-of-function screens. We characterize EVI1-controlled transcriptional programs in cell culture and in vivo, perform CRISPR screens and identify the ETS-related transcription factor ERG as the only gene that is specifically required for EVI1-driven AML. ERG is transcriptionally activated by EVI1 and overexpressed in EVI1-rearranged AML patients. ERG suppression selectively induces terminal differentiation of leukemia cells. EVI1 becomes dispensable for leukemia cells upon ectopic expression of ERG, indicating that key functions of EVI1 are mediated through aberrant activation of ERG. Interfering with this regulatory axis may therefore provide new entry points for rational therapies.

2022-10-11 | GSE195497 | GEO

Oncogene EVI1 Drives Acute Myeloid Leukemia Via a Targetable Interaction with CTBP2

Project description:Acute myeloid leukemia (AML) driven by the activation of EVI1 due to chromosome 3q26/MECOM rearrangements is incurable with current chemotherapy regimens. Insight into the mechanism by which EVI1 drives myeloid transformation is needed to target EVI1 in those leukemias. Here we demonstrate recurrent interaction of CTBP1/2 with a unique PLDLS motif in EVI1, which is indispensable for leukemic transformation of 3q26/MECOM rearranged AML. A PLDLS competitor construct outcompetes EVI1 to CTBP1/2 binding and inhibits AML proliferation in xenotransplant models. This proof-of-concept study opens the possibility to target one of the most incurable forms of AML using specific inhibitors directed to EVI1/CTBP1/2 interaction. Our findings have important implications for other tumour types with aberrant expression of EVI1 or other oncogenic transcription factors that also depend on CTBP1/2 interaction.

2023-07-13 | PXD043333 | Pride

Oncogene EVI1 Drives Acute Myeloid Leukemia Via a Targetable Interaction with CTBP2

2024-05-21 | PXD048760 | Pride

Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia

Project description:Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia

| PRJNA787920 | ENA

Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia II

Project description:Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia II

| PRJNA835052 | ENA

Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia [K562_RNA-seq]

Project description:Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia [K562_RNA-seq]

| PRJNA787926 | ENA

Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia [mouse_RNA-seq]

Project description:Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia [mouse_RNA-seq]

| PRJNA787924 | ENA

Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia (ChIP-Seq)

Project description:Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia (ChIP-Seq)

| PRJNA835058 | ENA

Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia (RNA-Seq)

Project description:Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia (RNA-Seq)

| PRJNA835057 | ENA

Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia [ChIP-seq]

Project description:Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia [ChIP-seq]

| PRJNA787927 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data